Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Status
Conditions
Details and patient eligibility
About
The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.
Full description
This is an exploratory study involving blood coagulation assays in a select group of individuals receiving treatment for their congenital or acquired bleeding or clotting disorder at UTHealth Houston. The ROTEG is a newly developed coagulation analyzer which allows the continuous assessment of whole blood coagulation from the formation of the first fibrin fibers and activated platelets, to the formation of a three-dimensional whole blood clot until the eventual dissolution of the clot. This device will not be used as a diagnostic or procedure tool. No recommendations regarding interpretation of the results or implications for future treatment will be provided.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria: patients with congenital or acquired bleeding or clotting disorders who have provided informed consent and/or assent
Exclusion Criteria: poor venous access
Trial contacts and locations
Loading...
Central trial contact
Katherine Addy, RN, BSN, MPH; Daisy Garcia, RN, BSN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal